Encouraging Results for Multiple Sclerosis Treatment
Topic: Multiple Sclerosis (MS)
Author: Hard to Treat Diseases
Published: 2010/06/03
Contents: Summary - Introduction - Main Item - Related Topics
Synopsis: Hard To Treat Diseases (HTDS.PK) Scientists report results that are encouraging for the future of Multiple Sclerosis Treatment.
Introduction
Hard To Treat Diseases (HTDS.PK) Scientists report results that are encouraging for the future of Multiple Sclerosis Treatment.Main Item
Hard to Treat Diseases, Inc. (HTDS:PK), www.htdsmedical.com announced today that researchers from its Slavica BioChem (www.slavicabiochem.com) division in Belgrade made a great progress in the experimental findings to aid in the suppression or ultimately cure of Multiple Sclerosis which are comparable with investigations of other MS-Research groups around the world.
In a recent press release posted on May 24, 2010 Abbott, and Biogen Idec. announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS), one of the most common neurological disorders that affects more than 2.5 million people worldwide.
This study is based on investigations of researchers from University Hospital, Basel, Switzerland. Dr Ludwig Kappos, M.D., Head, MS-Research Group, and lead investigator for the study said: "As shown in previous studies, daclizumab appears to selectively target immune cells that are thought to become activated in MS and cause damage to the central nervous system. Daclizumab is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at low levels on resting T-cells and at high levels on T-cells that are thought to become activated in response to MS. Daclizumab is believed to work by selectively targeting these activated T-cells without causing general T-cell depletion leading to reduction in the number of new or enlarged MS lesions."
Researchers in Belgrade are also making progress in suppression of immune response in MS using another immunomodulatory approach that involved application of purine nucleoside analogues: Ribavirin (FDA approved drug used in human clinical practice for 20 years) and Tiazofurin (orphan-drug). These drugs act primarily by inhibition of Inosine Monophosphate Dehydrogenase (IMPDH), a rate limiting enzyme in de novo purine synthesis pathway causing interruption of cell metabolism. Importantly, this exhaustion of purine pools had a more potent effect on activated lymphocytes than on the other cell types, since salvage pathways for the production of guanine nucleosides do not operate in T- and B cells. In this way, Ribavirin and Tiazofurin also work by selectively targeting activated T-cells. Prof Mirjana Stojiljkovic, the leader of IBISS research team, and Medical Advisor of Slavica BioChem division said: "We have shown promising results in decreasing severity of clinical symptoms and duration of MS induced in experimental animals, and radical reduction of mortality and degree of disability. Administration of ribavirin and Tiazofurin attenuated proliferation of auto-reactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. Similarly to our colleagues from Switzerland we have observed that the severity of treatment side effects of used substances was low and disappeared after cessation of drug application. These results are encouraging for the future of MS therapy."
Explore Related Topics
1 - New Multiple Sclerosis Treatment Clinical Trial Begins Enrollment - Clinical trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) begins enrollment.
2 - Stigma Increases Risk of Depression for People with Multiple Sclerosis - Those with MS who feel stigmatized are more likely to have depression, having a support system of friends and family and a sense of autonomy may help reduce the harmful effects of stigma..
3 - $7M MS Progression Cohort to Research Multiple Sclerosis in Canada - Research proposals will invite researchers to establish a Canadian cohort of people living with MS to study progression in the disease.
4 - How Can We Predict Whose Multiple Sclerosis Will Worsen? - Multiple Sclerosis study brings us closer to understanding which older adults with MS may be at higher risk of getting worse.
5 - Cladribine Significantly Reduces Brain Atrophy in Patients with Multiple Sclerosis - Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years.
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): Hard to Treat Diseases. (2010, June 3). Encouraging Results for Multiple Sclerosis Treatment. Disabled World. Retrieved October 11, 2024 from www.disabled-world.com/health/autoimmunediseases/ms/ms-treatment-results.php
Permalink: <a href="https://www.disabled-world.com/health/autoimmunediseases/ms/ms-treatment-results.php">Encouraging Results for Multiple Sclerosis Treatment</a>: Hard To Treat Diseases (HTDS.PK) Scientists report results that are encouraging for the future of Multiple Sclerosis Treatment.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.